Decorin: A Growth Factor Antagonist for Tumor Growth Inhibition by Järvinen, Tero AH & Prince, Stuart
Review Article
Decorin: A Growth Factor Antagonist for
Tumor Growth Inhibition
Tero A. H. Järvinen1,2 and Stuart Prince1
1School of Medicine, University of Tampere, 33014 Tampere, Finland
2Department of Orthopedics & Traumatology, Tampere University Hospital, 33521 Tampere, Finland
Correspondence should be addressed to Tero A. H. Ja¨rvinen; blteja@uta.fi
Received 27 July 2015; Accepted 21 October 2015
Academic Editor: Jean Claude Dussaule
Copyright © 2015 T. A. H. Ja¨rvinen and S. Prince. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Decorin (DCN) is the best characterized member of the extracellular small leucine-rich proteoglycan family present in connective
tissues, typically in association with or “decorating” collagen fibrils. It has substantial interest to clinical medicine owing to its
antifibrotic, anti-inflammatory, and anticancer effects. Studies on DCN knockout mice have established that a lack of DCN is
permissive for tumor development and it is regarded as a tumor suppressor gene. A reduced expression or a total disappearance of
DCN has been reported to take place in various forms of human cancers during tumor progression. Furthermore, when used as
a therapeutic molecule, DCN has been shown to inhibit tumor progression and metastases in experimental cancer models. DCN
affects the biology of various types of cancer by targeting a number of crucial signaling molecules involved in cell growth, survival,
metastasis, and angiogenesis.The active sites for the neutralization of different growth factors all reside in different parts of theDCN
molecule. An emerging concept that multiple proteases, especially those produced by inflammatory cells, are capable of cleaving
DCN suggests that native DCN could be inactivated in a number of pathological inflammatory conditions. In this paper, we review
the role of DCN in cancer.
1. Introduction
Decorin (DCN) is the best characterized member of the
small leucine-rich proteoglycan (SLRP) family of extracel-
lular matrix (ECM) proteins. Due to its close interactions
with collagen fibers in the ECM—that is, DCN “decorates”
collagen fibers—the proteoglycan was named decorin early
on [1]. DCN was initially cloned in 1986 and thought at the
time to be a structural constituent of the ECM [1]. However,
soon it was established that DCN had a role beyond just
a structural component of the ECM, as it became evident
that it influenced cellular functions such as proliferation,
spreading, migration, and differentiation, as well as being a
physiological regulator of inflammation [2–5]. Some of these
early findings were derived from tumor cells [2–5], where it
was shown that DCN inhibited cancer cell proliferation and
spreading. These studies sparked a two-decade-long quest
that established DCN as a promising antitumor agent to treat
human cancer patients [6].
Mammalian DCN contains a monomeric protein core
of 42 kDa and a single chondroitin/dermatan sulfate gly-
cosaminoglycan (GAG) chain, attached to a serine residue
near the N terminus [1, 7] (Figures 1 and 2). DCN exists as
a dimer in physiological solutions [8, 9] and as a monomer
when bound to collagen [10] (Figures 1 and 2) and is the
best characterized member of the growing family of SLRPs
[8, 9]. Structurally, it has a domain of tandem leucine-rich
repeats (LRRs, altogether 12 LRRs), flanked on both sides
by two cysteine-rich regions [8, 9] (Figures 1 and 2). SLRPs
have been grouped into three different classes on the basis of
gene organization, amino acid sequence similarity, number
of LRRs, and the spacing of cysteine residues in the N-
terminal segment [8]. DCN belongs to class I SLRPs with
biglycan (BGN) and asporin [8, 11].The structural similarities
between different SLRPs provide an explanation as to why
they share some of their biological functions [11–13]. DCN
has been implicated to play a role in the development and
progression of cancer and a substantial amount of work has
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Figure 1: Structure of decorin: mammalian decorin (DCN) contains a monomeric protein core of 42 kDa and a single chondroitin/dermatan
sulfate glycosaminoglycan (GAG) chain. DCN exists as a dimer in physiological solutions and is the best characterizedmember of the growing
family of SLRPs. Structurally, it has a domain of tandem leucine-rich repeats (LRRs, altogether 12 LRRs), flanked on both sides by two cysteine-
rich regions. Decorin dimer structure (from PDB 1XKU). Images prepared with JMOL program. The N-terminus is in the “middle” of the
antiparallel homodimer.
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Figure 2: Decorin interacts with multiple growth factor signaling pathways crucial for cancer growth. Schematic drawing of the molecular
structure of decorin (DCN). All four domains, I–IV, of decorin core protein are indicated. DCN has a monomeric protein core and a
single chondroitin/dermatan sulfate glycosaminoglycan (GAG) chain. Structurally, it has a domain of tandem leucine-rich repeats (LRRs),
flanked on both sides by two cysteine-rich regions. DCN interacts with a wide set of different signaling molecules; among them are different
isoforms of transforming growth factor-𝛽 (TGF-𝛽), platelet-derived growth factor (PDGF), epidermal growth factor receptor (EGFR), and
ErbB1–4 receptor tyrosine kinases, myostatin (MyoS), connective tissue growth factor/CCN2 (CTGF), thrombospondin (Thbs), collagen
(Col), and fibronectin (FN), implicated in cancer progression. The active/binding sites of DCN for TGF-𝛽, CCN2, c-Met, and EGFR
neutralization/binding all reside in different parts of the DCN molecule. Thus, in theory, a single DCN molecule could simultaneously
sequester multiple important mediators of tumor growth and antagonize multiple signaling pathways crucial for tumor growth and
progression. Thus, owing to this multifunctionality, DCN may exert its anticancer effects through multiple molecular approaches that all
contribute to varying degree to its biological effects on cancer cells and tumor environment.
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been published on its therapeutic anticancer effects. We will
review the role of DCN in cancer development and highlight
its vast therapeutic anticancer potential in this review article.
2. Loss of DCN Leads to
Spontaneous Tumor Development
DCN knock-out (KO) mice are fertile and show no obvious
malformations in their tissues [14].Their skin and tendons are
mechanically fragile owing to theDCN function of regulating
collagen fibrillogenesis [14]. When a double KO of DCN
and another closely related SLRP, BGN, was generated, the
phenotype in the double-KO mice was more severe than
in the DCN KO mice [12]. The DCN-BGN double-KO
phenotype is reminiscent of a specific subtype of Ehlers-
Danlos syndrome (EDS), the progeroid variant, a clinically
and genetically heterogeneous connective tissue disorder
characterized by skin hyperextensibility, joint hypermobility,
and tissue fragility [12, 15]. Taken altogether, the presence
of BGN compensates for the loss of DCN in the DCN KO.
In this context, it is worth noting that asporin shares the
collagen binding site with DCN [11]. Theoretically, asporin
could compensate for both DCN and BGN in double-KO
animal and alleviate the phenotype caused by the absence of
its two family members.
Despite the compensatory effect of BGN (and the poten-
tial compensatory role of asporin) in the absence of DCN,
30% of DCN KO mice developed spontaneous intestinal
tumors and a high-risk diet enriched in fat amplified and
accelerated the tumor development and growth initiated
by DCN deficiency [16]. Interestingly, E-cadherin, a pro-
tein that regulates cell-cell adhesion, epithelial-mesenchymal
transition, and metastasis, was almost completely lost from
the DCN KO intestine, and loss of DCN and E-cadherin
accelerated colon cancer cell growth and invasion [16]. DCN
and p53 tumor suppressor double-KO mice, in turn, have a
significantly faster rate of lymphoma development than p53
KO alone and succumb to thymic lymphomas months earlier
than p53 KO mice [17]. Most recently, the absence of DCN
in KO mice has been shown to promote chemically induced
hepatic carcinogenesis [18, 19]. Genetic ablation of DCN led
to enhanced tumor occurrence as compared to wild-type
animals in different models of hepatic cancer [18, 19]. Taken
together, all of the data generated on DCN KO mice suggest
that DCN is a potent tumor suppressor gene [6, 16–19].
There have not been any mutations reported for DCN in
human malignancies, whereas such mutations cause human
disease called congenital stromal corneal dystrophy (CSCD),
the disease characterized by corneal opacities and vision
impairment [20].
3. Reduced Expression of
DCN in Human Tumors
A large number of publications fromdifferent types of human
cancers have shown that DCN expression in tumors is signif-
icantly reduced from the levels expressed in normal tissues or
very often totally lost from tumor tissue [21, 22].The reduced
or total absence of DCN expression has been reported to
take place in breast, colon, prostate, vascular, and bladder
cancers, liposarcomas, myelomas, and malignant peripherial
nerve sheath tumors [21–26]. In linewith these findings, there
is also evidence from human cancers that DCN expression
decreases with the malignant transformation of tumor cells,
its expression being lost in the transformation from benign
to malignant tumors or its expression being lowest or totally
absent in the most aggressive tumors [21–25, 27]. In support
of this concept, low levels of DCN in cancers are associated
with significantly poorer outcome and a shorter time to pro-
gression than with patients expressing higher levels of DCN
in breast, lung, and soft tissue cancers as well as in myeloma
[21–23, 28]. The reduced expression of DCN is not restricted
only to tumor cells in cancer progression; stromal expression
of DCN is also decreased by soluble factors secreted by
tumor cells [29–31]. Myeloma cells secrete CCL3 chemokine
that suppresses DCN expression in the surrounding bone
marrow stroma [31] because stromal/osteoblast derivedDCN
is known to inhibit myeloma cell proliferation and survival
[29, 31, 32]. Breast cancer cells, in turn, secrete periostin that
sequesters DCN and by doing so the cancer cells provide
themselves an opportunity to grow invasively and migrate
without inhibitory activity from DCN [30].
Very recently, the reduced DCN expression has been
linked to osteosarcoma development in Li-Fraumeni syn-
drome (LFS) [33]. It was shown that the LFS-cells exhibit
impaired expression of the imprinted gene H19 [33]. Restora-
tion of H19 expression in LFS-cells facilitated normal cell
differentiation and repressed tumorigenic potential. It was
found that H19 mediates suppression of LFS-associated
osteosarcoma formation through DCN [33].
4. DCN Sequesters
Transforming Growth Factor-𝛽
Transforming growth factor-𝛽 (TGF-𝛽) was the first growth
factor DCN was identified to interact with [5] (Figure 2),
and it became evident that DCN effectively inhibits TGF-𝛽
induced cancer cell spreading and proliferation in different
cancer cell lines [5]. Later it was shown in different animal
models that DCN is very capable of reducing tissue fibrosis
and inflammation caused by TGF-𝛽 [4, 34–38]. The DCN
core protein binds to all isoforms of TGF-𝛽, namely, TGF-𝛽1,
TGF-𝛽2, and TGF-𝛽3 (Figure 2), although the chondroitin
sulfate GAG side chain of DCN slightly interferes with the
core protein’s binding of TGF-𝛽 [39]. Thus, DCN traps TGF-
𝛽 in the ECM before it can bind to its receptors on the
cell surface [36]. In addition to neutralizing all isoforms of
TGF-𝛽, DCN also binds and neutralizes another member
of the TGF-𝛽 superfamily capable of inducing fibrosis and
restricting tissue regeneration, myostatin [37, 40] (Figure 2).
In the case of myostatin inhibition, DCN sequestration shuts
down myostatin’s growth inhibitory effects on myofibers
and thus DCN stimulates skeletal muscle regeneration [37,
40, 41]. Due to its potency in reducing inflammation and
fibrosis, DCN has been proposed to be a physiological TGF-
𝛽 inhibitor that limits the duration of TGF-𝛽 responses in
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inflammation and tissue repair [4, 36]. This claim is sup-
ported by the pro-inflammatory phenotype identified in
DCN KO in different fibrotic disease models as well as
the inflammation suppressive effects of exogenous DCN
supplemented in experimental treatment trials [4, 34, 36, 42,
43].
5. DCN: A Pan-Receptor
Tyrosine Kinase Inhibitor
ErbB receptor tyrosine kinases (RTKs) are heavily involved in
the growth of several common human carcinomas [44, 45].
These receptors are amplified and overexpressed in a large
number of tumors, most notably in breast cancer, where the
ErbB2 gene at 17q12 is known to be amplified in 20% of the
carcinomas and known to drive cancer progression [44, 45].
DCN binds directly to the epidermal growth factor receptor
(EGFR/ErbB1) and inhibits its activity as well as the activity
of another member of the ErbB RTKs, namely, ErbBs2–4
[46–50] (Figure 2). After binding DCN, the ErbB receptors
dimerize and subsequently undergo caveolin-mediated inter-
nalization and degradation [50].
DCN is a pan-RTK inhibitor as it also inhibits other RTKs
outside of the ErbB family. It interacts with c-Met, hepatocyte
growth factor (HGF) receptor tyrosine kinase (Figure 2).
By binding to the c-Met receptor DCN induces a short
activation, which is then followed by a rapid inactivation
of the receptor by intracellular degradation [51, 52]. DCN
also binds and inhibits the biological function of vascular
endothelial growth factor receptor 2 (VEGFR2) (please see
Section 7 for more details) and insulin-like growth factor-1
receptor (IGF-IR) [53, 54].
6. Other Signaling Molecules Affected by DCN
In addition to TGF-𝛽 and the RTKs, DCN also interacts
with a wide set of different signaling molecules implicated
in cancer progression. In an analogous antagonism to TGF-
𝛽, DCN sequesters platelet-derived growth factor (PDGF)
before it can bind to its receptors on the surface of target
cells [55] (Figure 2). The DCN-provoked inhibition on the
PDGF-dependent phosphorylation of the PDGF receptor
results in the attenuation of cancer cell migration [19, 55].
DCN also binds and neutralizesmolecules such as connective
tissue growth factor (CTGF/CCN2), low-density lipopro-
tein receptor-related protein 1 (LRP-1), thrombospondin
(THBS), and Wnt-1-induced secreted protein 1 (WISP) [56–
59] (Figure 2). All of these molecules have been directly
shown to enhance cancer growth and progression in different
cancermodels and human cancers [56–59].The ECMprotein
periostin, which is abundantly expressed by a large number of
different human cancers, binds and neutralizes DCN [30].
The active/binding sites of DCN for TGF-𝛽, CCN2, c-
Met and EGFR neutralization/binding all reside in differ-
ent parts of the DCN molecule [57, 59] (Figure 2). Thus,
in theory, a single DCN molecule could simultaneously
sequester multiple important mediators of tumor growth and
antagonize multiple signaling pathways crucial for tumor
growth and progression [36] (Figure 2). Thus, owing to this
multifunctionality, DCN may exert its anticancer effects
through multiple molecular approaches that all contribute to
varying degree to its biological effects on cancer cells and
tumor environment [6] (Figure 2).
7. DCN in Angiogenesis
Tumors induce thegrowth of new blood vessels from preex-
isting ones. This process, angiogenesis, is a vital requirement
for tumor growth because the formation of new blood
vessels allows a variety of mediators, nutrients, and oxygen
to reach the rapidly growing tumor cells [60, 61]. DCN
has been implicated to be involved in the regulation of
angiogenesis with conflicting outcomes. In terms of cancer,
DCN has been shown to have an antiangiogenic effect on
tumor angiogenesis [62]. Among the RTKs DCN inhibits,
VEGFR2 inhibition is the most significant for DCN induced
inhibition of tumor angiogenesis [54]. DCN binds directly to
the ectodomain of VEGFR2 at a site that partially overlaps
with the canonical binding site for VEGF-A [54]. DCN
has been shown to inhibit tumor cell-mediated production
of the angiogenic molecules vascular endothelial growth
factor A (VEGF-A), hypoxia inducible factor-1𝛼 (HIF-1𝛼),
and c-Met, whilst simultaneously inducing the production of
the antiangiogenic, angiostatic molecules thrombospondin-
1 and tissue inhibitor of metalloproteinases 3 (TIMP3) [63,
64]. In addition to influencing the balance of anti- and
proangiogenic factors, the antiangiogenic mechanisms of
DCN in tumor angiogenesis involve autophagy [62]. Namely,
DCN induces the expression of paternally expressed gene
3 (Peg3), an imprinted tumor suppressor gene, and Peg3
relocates into autophagosomes [65]. DCN evokes Peg3-
dependent autophagy in both microvascular and macrovas-
cular endothelial cells leading to suppression of angiogenesis
[65].
On the other hand, there is also evidence for DCN
supporting angiogenesis outside of tumor angiogenesis [66,
67]. DCN has been shown to play a proangiogenic role
by supporting endothelial cell adhesion to type I collagen
(Figure 2) and to 𝛼1𝛽2-integrin and thus promoting the
integrin-collagen interaction [68]. DCN deficiency, in turn,
leads to impaired angiogenesis in the injured cornea [66],
while a decorin mimic supports endothelial cell proliferation
and migration [69]. Furthermore, DCN was also identified
as an angiocrine (endothelial cell derived growth factor for
organ-specific tissue regeneration) factor for endothelial cell-
driven liver regeneration [70]. Thus, depending on the cel-
lular and molecular microenvironment where angiogenesis
occurs, DCN can exhibit either a proangiogenic or an antian-
giogenic activity [71]. Nevertheless, DCN exhibits exclusively
antiangiogenic activity in tumorigenesis-associated angio-
genesis and in various inflammatory processes [70, 71].
8. DCN as a Therapeutic
Anticancer Drug In Vivo
Vast amounts of scientific data have shown that the
administration of DCN can inhibit tumor growth and
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progression in vivo. Early studies utilizing virus-mediated
gene therapy showedDCN transduced into tumor cells inhib-
ited the growth of lung, colon, and squamous cell carcinomas
in vivo [72]. DCN expression by osteosarcoma cells, in turn,
inhibited their capability to send distant metastases to the
lungs [73]. Similarly, virus-delivered DCN slowed the growth
of breast cancer and prevented its distant spreading, that
is, metastasis to various organs [74–76]. The expression of
DCN by virus-mediated gene therapy in an experimental
gliomamodel prolonged survival and inhibited tumor growth
[77, 78]. The size of the tumors was directly proportional
to the timing of the DCN gene transfer as well as to the
expression levels of DCN attained by the gene transfer [77].
The tumor growth inhibitory activity of DCN gene therapy
has also been shown in prostate and pancreatic cancermodels
[79, 80].
In addition to in vivo gene therapy studies, where DCN
has been expressed from within virus-infected cells, in vivo
tumor treatment studies with a recombinant DCN core
protein have been carried out with considerable success.
Treatment of A431 squamous cell carcinoma and breast
carcinomas transfected with DCN cDNA resulted in tumor
cell apoptosis, reduced EGFR signaling, and retarded tumor
growth [46, 49, 81]. Systemic administration of DCN protein
to treat breast cancer inhibited tumor growth effectively and
reduced metastatic spreading of the tumor cells [52, 82].
9. Inactivation of DCN by Protease Mediated
Cleavage in Human Pathologies
The multifunctional roles of DCN are due to its capacity to
modulate the activity of a wide variety of proteins, such as
growth factors or their cell surface receptors, and structural
matrix proteins, via direct binding. Impairment of DCN
binding to its partners due to aberrant DCN degradation is
linked to fibrotic diseases and fibrotic wound healing. Several
proteases as well as growth factors are known to be capable
of cleaving DCN making it inactive against some of the
growth factors or collagen it is capable of binding to. Amongst
different proteases, DCN has been shown to be cleaved
by matrix metalloproteinases-2 (MMP-2), MMP-3, MMP-
7, membrane type 1-matrix metalloproteinase (MT1-MMP),
cathepsin D, ADAMST-4 (adamalysin with thrombospondin
type 1 motifs), ADAMST-5, and interleukin-1𝛽 [83–86].
Furthermore, inflammatory cells produce proteases capable
of cleaving DCN. Cytotoxic lymphocytes produce granzyme
B, a serine protease, while neutrophils produce neutrophil
elastase, both of which are capable of cleaving DCN [87–90].
The cleavage ofDCNbyproteases derived from inflammatory
cells is of special significance, because recent evidence sug-
gests that DCN fragments can function as proinflammatory
signaling molecules, so-called damage-associated molecular
patterns (DAMPs), capable of inducing sterile inflammation
[91]. DAMPs are recognized by pattern recognition receptors
(PRRs), such as Toll-like receptors (TLR), and can trigger
an inflammatory response [91]. Whether the DCN-induced
sterile inflammation has any clinical significance is a relevant
question, as an overwhelming amount of evidence points
to DCN having a substantial anti-inflammatory effect in
inflammatory, fibrotic diseases; phenotype in the absence of
DCN (KO) is always both proinflammatory and profibrotic,
whereas the in vivo treatment trials with exogenous DCN
exclusively report both anti-inflammatory as well as antifi-
brotic effects [2, 4, 34, 36–38, 92].
Inactive DCN fragments generated by protease cleavage
as well as the general reduced expression of DCN have
been linked to human pathologies [93]. Namely, catabolic
fragments of human DCN have been identified from scars
and fibrotic diseases, and the impairment of DCN binding
to its partners due to aberrant DCN degradation has been
directly linked to fibrotic wound healing [94, 95]. Recently,
it was shown that UV light exposure on skin can induce
the expression of granzyme B, which cleaves DCN and
leads to the appearance of wrinkles and the loss of normal
collagen density in the skin [87]. In a similar fashion, it
has been shown that DCN cleavage by granzyme B leads to
aneurysm ruptures and subsequent deaths of the animals in
an experimental aortal aneurysm model [88]. Furthermore,
granzyme B can activate TGF-𝛽 [87]. In other words, the
simultaneous cleavage of antifibrotic DCN and the activation
of profibrotic TGF-𝛽 by granzyme B turn on a “profibrotic
program” in inflammatory situations.
Furthermore, it has been shown that themajority of DCN
exists in a cleaved, inactive form called “decorunt” in aged
human skin, whereas most of the DCN in young human
skin is in its full size [94, 95]. As DCN is involved in the
regulation of collagen fibrillogenesis, it has been postulated
that the loss of skin extensibility and fragility associated
with aging is related to DCN being cleaved into inactive
“decorunt” fragments [94, 95]. Interestingly, none of the
DCN cleavage sites reported for different proteases generate
the DCN fragments identified in “decorunt” [94, 95]. Thus,
one can postulate on the existence of as yet unidentified
protease(s) capable of cleaving and inactivatingDCN[94, 95].
10. Limitations of DCN
Despite the vast amount of positive anticancer and antifi-
brotic results obtained with DCN treatment in various
animal models, lack of any detectable toxicity, and extensive
preclinical work conducted on it, DCN has not reached the
clinic as a drug. There might be several reasons for that, such
as an inadequate half-life in the circulation and the need for
high dosing, but another reason is the fact thatDCN is hard to
mass-produce in a fashion that meets the regulatory criteria
for human drugs. Namely, DCN is a proteoglycan, and the
heterogeneity of its single GAG chain makes recombinant
DCN produced in mammalian cells heterogeneous in size
and composition [5]. The GAG chain is not needed for the
antifibrotic activity of DCN [39], most of the anticancer
effects of DCN have been generated with recombinant DCN
with noGAGattached to it, andmost of the interactionsDCN
has with growth factors or their receptors are through direct
binding to the DCN core protein. The GAG is attached to
a serine residue at position 4 of DCN [1], and it is possible
to produce recombinant DCN without GAG attached to it
6 BioMed Research International
1
2 3
4
Decorin CAR
TGF-𝛽1
HSPG
S-S
TGF-𝛽RII
TGF-𝛽RI
Figure 3: Schematic representation of themechanism of action of themultifunctional therapeutic molecule CAR-decorin. CAR-decorinA is
a systemically administered, target-seeking, multifunctional biotherapeutic that inhibits numerous growth factors involved in tumor growth
and progression. The molecule can be targeted to the angiogenic vasculature, whether it is induced by injury or by rapid cancer growth,
taking place at any organ of the bodyB (or multiple organs, i.e., metastases, simultaneously). The CAR homing peptide targets angiogenic
vasculature B and as it is a potent cell and tissue penetrating peptide, it can penetrate deep into target organ C. Thus, the peptide (and
any payload attached to it) then extravasates into surrounding tissue C, where it binds to its receptor(s) on the cell surface of the target
cellsC. CAR binding to heparan sulfate proteoglycans provides docking sites in the proximity of such growth factors as TGF-𝛽1 and TGF-
𝛽2D, facilitating the neutralization of these growth factors by the therapeutic part of the molecule, decorinD. This mechanism results in a
therapeutic response. Picture byHelena Schmidt; reproduced with permission from FinnishMedical Journal Duodecim (originally published
in [96]).
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by simply mutating the serine residue critical for the GAG
attachment [7, 97].
11. Recombinant DCN Variant with
Enhanced Biological Activity
As the manufacturing issues of DCN can be solved fairly
easily by a simple site-directed mutagenesis [7], further
enhancement of its biological activity could make it an
even more appealing drug candidate to pursue as a human
therapeutic drug. We have recently attained that goal by
developing a systemically administered, targeted, for exam-
ple, inflammation- and angiogenesis-homing version ofDCN
core protein [34, 36, 98] (Figure 3). The angiogenesis- and
inflammation-specificity of our enhanced DCN core protein
is obtained by fusion to a small peptide that functions
as an address tag and delivers systemically administered
DCN to angiogenic and inflammatory vasculature [34, 36]
(Figure 3). This small peptide, dubbed “CAR” (its sequence
being CARSKNKDC) homes specifically to angiogenic blood
vessels forming in tumors and regenerating tissues (such as
wounds) [99, 100] and can deliver increased amounts of DCN
in a tissue-specific manner with a significant therapeutic
advantage over ordinary DCN core protein [34] (Figure 3).
Furthermore, the fusion ofCAR to recombinantDCN further
enhances its neutralization of TGF-𝛽 stimulated cancer cell
proliferation and spreading significantly [34] (Figure 3). The
molecular explanation for the enhanced biological activity
of CAR-DCN is that the CAR peptide binds to heparan
sulfate proteoglycans (HSPGs) on cells [34, 99]. TGF-𝛽1
and TGF-𝛽2, in turn, also bind heparan sulfate and HSPG
binding increases their biological activity (Figure 3). Thus,
CARmediated binding of CAR-DCN toHSPGsmay enhance
the neutralizing effect of the fusion protein by bringing it
into the proximity of the HSPG-binding TGF-𝛽s [34, 36, 97]
(Figure 3). The CAR peptide has also been recently shown to
target inflammatory vasculature, but not normal vasculature,
in diseases affecting lungs [100–105] and to deliver different
pharmaceutical agents (even large nanoparticle conjugates
containing drugs) in target organ-specific fashion to diseased
lungs [101–105]. Furthermore, CAR peptide has been used
successfully to target mesenchymal stem cells to infarcted
myocardium [106, 107]. Thus, CAR-targeted DCN could also
be useful in the treatment of other conditions outside of
cancer and healing wounds in which nontargeted DCN has
shown activity and where there is angiogenesis or inflamma-
tion affecting nearby vasculature (Figure 3).
12. Conclusion
DCN is a well-studied member of the extracellular small
leucine-rich proteoglycan family present in a variety of tissues
and has substantial interest to clinical medicine owing to its
antifibrotic and anticancer effects. Studies on DCN knockout
mice have established that a lack of DCN is permissive for
tumor development and it is regarded as a tumor suppressor
gene. A reduced expression or a total disappearance of DCN
has been reported to take place in various forms of human
cancers during tumor progression. Furthermore, when used
as a therapeutic molecule, DCN has been shown to inhibit
tumor progression and metastasis in experimental cancer
models. DCN affects the biology of various types of cancer
by directly or indirectly targeting large numbers of crucial
signaling molecules involved in cell growth, survival, metas-
tasis, autophagy, and angiogenesis. The active sites for the
neutralization/binding of different growth factors all reside
in different parts of the DCN molecule. Multiple proteases,
especially those produced by inflammatory cells, are capable
of cleaving and inactivatingDCN, indicating that DCN could
be inactive in a number of pathological diseases involving an
inflammatory component. Thus, the effective application of
DCN core protein in human medicine will require strategies
to deliver large amounts of the intact and functional protein
specifically to where it is most needed, as well as other
possible enhancement strategies. The fusion of DCN core
protein together with the angiogenesis- and inflammation-
homing peptide “CAR” is a significant step in this direction.
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